Table 6.

Neuraminidase inhibitor use and hospital isolation facility use

	POCT (n=360)	Control (n=354)	Difference (95% CI)	Odds ratio (95% CI)	Number needed to test (95% CI)	p value
Neuraminidase inhibitor use
Neuraminidase inhibitor used (total)	66 (18%)	51 (14%)	3·9% (−1·5 to 9·4)	1·33 (0·89 to 1·99)	..	0·16
Used in influenza-positive patients	54/66 (82%)	24/51 (47%)	34·7% (17·5 to 52·0)	5·06 (2·20 to 11·65)	3 (1·9 to 5·5)	0·0001
Used in influenza-negative patients	12/66 (18%)	27/51 (53%)	..	..	..	..
Influenza-positive patients treated with neuraminidase inhibitor*	52/57 (91%)	24/37 (65%)	26·4% (9·6 to 43·2)	5·63 (1·80 to 17·60)	4 (2·3 to 10·7)	0·0026
Duration of neuraminidase inhibitor use in influenza-negative patients (doses)†	2·0 (2·6)	6·1 (4·1)	−4·1 (−6·3 to −1·9)	..	..	0·0006
Time to first dose of neuraminidase inhibitor (h)*	8·8 (15·3)	21·0 (28·7)	−12·2 (−24·9 to 0·5)	..	..	0·0597
Isolation facility use‡
All patients isolated	63/191 (33%)	49/194 (25%)	7·7% (−1·3 to 16·8)	1·45 (0·94 to 2·27)	..	0·12
Isolated with confirmed respiratory virus infection§	32/191 (17%)	17/194 (9%)	8·0% (1·3 to 14·7)	2·10 (1·12 to 3·92)	13 (6·8 to 73·2)	0·0217
Influenza-positive patients isolated*	20/27 (74%)	13/23 (57%)	17·6% (−8·8 to 43·9)	2·20 (0·67 to 7·24)	..	0·24
Time to isolation (days)¶	0·5 (0·5)	1·0 (0·4)	−0·5 (−0·9 to −0·2)	..	..	0·0071
Time to de-isolation (days)||	1·0 (0·0)	3·1 (2·2)	−2·1 (−3·6 to −0·7)	..	..	0·0057

Data are n (%) or mean (SD). Medians are reported in the appendix for completeness. POCT=point-of-care testing.

^*For hospitalised influenza-positive patients only.

^†Oseltamivir is given twice daily.

^‡Side room data only available for the second season of the study (PCOT n=191; control n=194).

^§Includes influenza and respiratory syncytial virus.

^¶For patients not empirically isolated at admission, but subsequently found to be influenza positive.

^||For patients isolated empirically on admission for suspected influenza infection, but subsequently found to be influenza negative.